Source comparison
GHRP-2 Acetate vs MK-677 — Key Differences | Real Peptides
Research teams comparing growth hormone secretagogues often assume GHRP-2 Acetate and MK-677 (ibutamoren) are interchangeable because both elevate endogenous GH. That's the only similarity. GHRP-2 functions as a short-acting injectable peptide requiring multip
This comparison does not assign a generated winner or score.
- Research teams comparing growth hormone secretagogues often assume GHRP-2 Acetate and MK-677 (ibutamoren) are interchangeable because both elevate endogenous GH. That's the only similarity. GHRP-2 functions as a short-acting injectable peptide requiring multiple daily administrations to mimic pulsatile GH secretion, while MK-677 operates as an orally bioavailable GH secretagogue with sustained activity over 24 hours. The mechanisms, administration protocols, and research applications diverge entirely from that point.
- Our team at Real Peptides has supplied both compounds to research institutions for over a decade. The choice between GHRP-2 and MK-677 comes down to three factors most comparative analyses never address: pulsatile vs sustained GH release patterns, injection fatigue in multi-week protocols, and receptor desensitisation risk.
- What is the difference between GHRP-2 Acetate and MK-677?
- GHRP-2 Acetate is a synthetic hexapeptide (6 amino acids) that binds to ghrelin receptors in the pituitary gland, triggering acute GH pulses within 20–30 minutes of subcutaneous injection. MK-677 is a non-peptide ghrelin receptor agonist and growth hormone secretagogue that sustains elevated GH and IGF-1 levels for 24+ hours after a single oral dose. GHRP-2 mimics the body's natural pulsatile GH secretion pattern; MK-677 produces steady-state elevation without the sharp peaks and troughs.
- The core distinction isn't just administration route. It's pharmacodynamics. GHRP-2 clears the system within 4–6 hours, requiring 2–3 daily doses to maintain therapeutic GH levels throughout a research cycle. MK-677's half-life of approximately 24 hours allows once-daily dosing with consistent plasma concentration. Both compounds elevate IGF-1 as a downstream marker, but the kinetic profiles produce measurably different physiological responses in tissue-building and metabolic studies.